Suzhou Leitai Medical Technology Secures Tens of Millions in Series B Funding Led by CITIC to Advance Precision Radiotherapy Solutions

VCBeat (WeChat: vcbeat) has learned that, recently,withFully Independent Intellectual Property RightsLarge-scale radiotherapy equipment- Manufacturer of Medical Linear AcceleratorsSuzhou Raytine Medical Technology Co., Ltd.(“Suzhou Leitai”) completed a Series B financing round worth tens of millions of yuan, exclusively led by CITIC Xingye Investment Group Co., Ltd. (“CITIC Xingye”), the capital operation platform of CITIC Group.

As the “crown jewel” of high-end medical equipment, medical linear accelerators have long been monopolized by a few foreign brands. Suzhou Raytium, one of the domestic companies driving import substitution, has specialized in the radiotherapy industry for decades and possessesWorld's First Orthogonal Dual-Layer Grating Technology, with higher tumor conformality, greater treatment efficiency, and lower leakage rate, demonstrating significant clinical value.This technology is globally leading, breaking the technological monopoly of foreign manufacturers.This product has been exported overseas.Achieved a breakthrough in the export of domestic linear accelerators,The product's performance has gained international recognition.

This investment support from CITIC Industrial Investment will accelerate the company’s growth, strengthen the development of domestically produced solutions, speed up the replacement of imported high-end medical equipment with domestic alternatives, reduce national healthcare expenditures at the source, and contribute to the widespread adoption of radiotherapy and the improvement of cancer survival rates among the Chinese population.

Following this round of financing, Suzhou Raytune will increase its R&D investment in precise radiotherapy technology products, continuously iterate and expand its offerings to achieve sustainable product innovation; meanwhile, it will further explore the market, enhance corporate brand influence, and strive for an initial public offering in the capital markets as soon as possible.